Ixensor Co

Ixensor Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ixensor Co (6734.TWO) as of Nov 5, 2026 is -45.71 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -46.09 M TWD — a change of -0.81% (higher).

EBITDA

-45.71 MTWD

YoY

-0.81%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ixensor Co is 2025 -45.71 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ixensor Co was 2024 -46.09 M TWD. It decreases by -0.81% higher compared to the previous year.

The Ixensor Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-109.33 M TWD
Jan 1, 2019
-109.04 M TWD
Jan 1, 2020
-80.03 M TWD
Jan 1, 2021
-81.48 M TWD
Jan 1, 2022
-5.23 M TWD
Jan 1, 2023
-63.04 M TWD
Jan 1, 2024
-46.09 M TWD
Jan 1, 2025
-45.71 M TWD
The Ixensor Co EBITDA history
YEAREBITDAYoY
-45.71 MTWD-0.81%
-46.09 MTWD-26.89%
-63.04 MTWD+1,104.82%
-5.23 MTWD-93.58%
-81.48 MTWD+1.81%
-80.03 MTWD-26.60%
-109.04 MTWD-0.27%
-109.33 MTWD+0.40%
-108.90 MTWD+2.74%
-106.00 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ixensor Co Stock analysis

What does Ixensor Co do? iXensor Co., Ltd. generates revenue through its PixoTest Blood Glucose Monitoring System and ovulation detection system, targeting individuals managing diabetes and reproductive health. The company's technology platform measures biochemical parameters including blood sugar, luteinizing hormone, and cholesterol, providing data for diabetes management services. Its integrated medical device solutions serve customers seeking self-monitoring tools for chronic conditions and fertility tracking. The firm's products are designed for direct consumer use, with the PixoTest system offering blood glucose monitoring and the ovulation detection system supporting female hormone cycle management. These solutions leverage the company's platform to deliver personalized health insights without requiring third-party partnerships. The target segments include patients with diabetes and individuals tracking fertility cycles through biochemical monitoring. Ixensor Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ixensor Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ixensor Co is -45.71 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ixensor Co changed from -46.09 M TWD to -45.71 M TWD, representing a -0.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Ixensor Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Ixensor Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Ixensor Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Ixensor Co